首页 正文

Inflammatory bowel diseases. 2025 Jun 13:izaf119. doi: 10.1093/ibd/izaf119 Q14.32025

Safety and Effectiveness of QingDai (Indigo naturalis) in Children With Mild-to-Moderate Ulcerative Colitis: A Short-Term 6-Week Open-Label Trial

青黛治疗轻中度活动性溃疡性结肠炎儿童短期疗效及安全性观察:开放式临床试验研究 翻译改进

Dotan Yogev  1  2, Yael Weintraub  3  4  5, Oren Ledder  1  2, Manar Matar  3  4  5, Alex Krauthammer  4  6  5, Zivia Shavit-Brunschwig  1, Amichay Rotstein  4  7  5, Max E Godfrey  8, Amit Assa  1  2, Raanan Shamir  3  4  5, Dan Turner  1  2  9, Nir Salomon  4, Esther Orlanski-Meyer  1  2, Dror S Shouval  3  4  5

作者单位 +展开

作者单位

  • 1 Shaare Zedek Medical Center, Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition, Jerusalem, Israel.
  • 2 Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
  • 3 Schneider Children's Medical Center of Israel, Institute of Gastroenterology, Nutrition and Liver Diseases, Petach Tikva, Israel.
  • 4 Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
  • 5 Gray Faculty of Medical & Health Sciences, School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • 6 Pediatric Gastroenterology Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.
  • 7 Department of Pediatric Cardiology, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.
  • 8 Pediatric Cardiology Unit, Shaare Zedek Medical Center, Jerusalem, Israel.
  • 9 The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem, Israel.
  • DOI: 10.1093/ibd/izaf119 PMID: 40512056

    摘要 中英对照阅读

    Copyright © Inflammatory bowel diseases. 中文内容为AI机器翻译,仅供参考!

    相关内容

    期刊名:Inflammatory bowel diseases

    缩写:INFLAMM BOWEL DIS

    ISSN:1078-0998

    e-ISSN:1536-4844

    IF/分区:4.3/Q1

    文章目录 更多期刊信息

    全文链接
    引文链接
    复制
    已复制!
    推荐内容
    Safety and Effectiveness of QingDai (Indigo naturalis) in Children With Mild-to-Moderate Ulcerative Colitis: A Short-Term 6-Week Open-Label Trial